基于加权TOPSIS法的注射用替加环素药物利用评价
|
摘要
目的:建立基于加权优劣解距离法(TOPSIS)的替加环素药物利用评价细则,为临床合理使用替加环素提供参考。方法:以注射用替加环素说明书为基础,参照相关规范及文献,建立基于加权TOPSIS法的替加环素药物利用评价细则,并以此为依据,对某院2012-2017年100例住院患者替加环素的使用情况进行评价。结果:评价的100份病历中,与最优方案接近程度大于70%的2例(占比2.0%),接近程度50%～70%的63例(占比63.0%),接近程度40%～50%的35例(占比35.0%)。结论:基于加权TOPSIS法的替加环素药物利用评价方法可用于替加环素药物利用评价。评价结果显示替加环素不合理使用现象较为普遍,医院需加强管理,进一步规范替加环素的合理使用。
OBJECTIVE To establish a method based on the weighted technique for order preference by similarity to ideal solution(TOPSIS)method for evaluating the use of tigecycline,and to provide a reference for rational use of tigecycline.METHODS Based on tigecycline instructions,referring to related specifications and literatures,and based on the weighted TOPSIS method,the evaluation rules of tigecycline were established.Based on this,the use of tigecycline in 100 inpatients of a hospital from 2012 to 2017 was evaluated.RESULTS Among 100 cases,relative proximity of 2 cases(2.0%)was more than 70%;that of 63 cases(63.0%)was between50% and 70%;that of 35 cases(35.0%)was between40% and 50%.CONCLUSION It is reasonable and feasible to adopt weighted TOPSIS as the drug use evaluation method for tigecycline.The evaluation results show that unreasonable use of tigecycline is common,and the hospital needs to strengthen management to further regulate the rational use of tigecycline.
OBJECTIVE To establish a method based on the weighted technique for order preference by similarity to ideal solution(TOPSIS)method for evaluating the use of tigecycline,and to provide a reference for rational use of tigecycline.METHODS Based on tigecycline instructions,referring to related specifications and literatures,and based on the weighted TOPSIS method,the evaluation rules of tigecycline were established.Based on this,the use of tigecycline in 100 inpatients of a hospital from 2012 to 2017 was evaluated.RESULTS Among 100 cases,relative proximity of 2 cases(2.0%)was more than 70%;that of 63 cases(63.0%)was between50% and 70%;that of 35 cases(35.0%)was between40% and 50%.CONCLUSION It is reasonable and feasible to adopt weighted TOPSIS as the drug use evaluation method for tigecycline.The evaluation results show that unreasonable use of tigecycline is common,and the hospital needs to strengthen management to further regulate the rational use of tigecycline.
引文
[1]Shi QP,Xu SC,Liu Y,et al.Establishment and Application of Clinical Pharmacy DUE Mode[J].J China Pharm(中国药房),2010,21(22):2104-2106.
[2]Pedersen CA,Schneider PJ,Scheckelhoff DJ.ASHP National Survey of Pharmacy Practice in Hospital Settings:Prescribing and Transcribing-2004[J].Am J Health Syst Pharm,2005,62(4):378-390.
[3]2013 national antibacterial drug clinical application special rectification activities program(2013年全国抗菌药物临床应用专项整治活动方案)[EB/OL].(2013-05-06)[2018-06-04].http://www.moh.gov.cn/mohyzs/s3585/201305/6042979f05cf49609e96410d7314ecae.shtmL.
[4]Antibacterial drug clinical application management method(抗菌药物临床应用管理办法)[EB/OL].(2012-04-24)[2018-06-04].http://www.moh.gov.cn/mohyzs/s3584/201205/54645.shtmL
[5]Guiding Principles for Clinical Application of Antibacterials(2015 Edition)(抗菌药物临床应用指导原则(2015年版)[EB/OL].(2015-07-24)[2018-06-04].http://www.nhfpc.gov.cn/yzygj/s3593/201508/c18e1014de6c45ed9f6f9d592b43db42.shtmL.
[6]Qu XY,Zhang SX,Yan HY,et al.Meta-analysis of safety induced by tigecycline in the therapy of infectious diseases[J].Chin J Pharmacoepidemiol(药物流行病学杂志),2015,24(3):142-147,151.
[7]Song Z,Xu YG,Xia XY,et al.Two cases of tigecycline in the treatment of intracranial infection caused by pan-resistant Acinetobacter baumannii[J].Chin J Neurotrauma Surg(Electronic Edition)(中华神经创伤外科电子杂志),2015,1(4):57-58.
[8]Dong W,Xie XQ,Kang Y.The interpretation of guideline of appropriate use of tigecycline[J].Chin J Evid-based Med(中国循证医学杂志),2016,16(1):30-32.
[9]Ramirez J,Dartois N,Gandjini H,et al.Randomized phase 2trial to evaluate the clinical efficacy of two high dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia[J].Antimicrob Agents Chemother,2013,57(4):1756-1762.
[10]Kadoyama K,Sakaeda T,Tamon A,et al.Adverse event profile of tigecycline:data mining of the public version of the U.S.Food and Drug Administration adverse event reporting system[J].Biol Pharm Bull,2012,35(6):967-970.
[11]Liu JB,Qu CY,Wang RH.Comprehensive evaluation and application of Tosis based on attribute AHM[J].Modern Preventive Msdicine(现代预防医学),2006,33(10):1862-1863.
[12]Wan F,Song JP.Application of Weighted TOPSIS Method in Comprehensive Evaluation of Hospital Medical Quality[J].Chin J Hosp Statistics(中国医院统计),2010,17(4):297-298.
[13]Li JM,Liu QO,Qu CY.Method for determining the weights of two indicators in comprehensive evaluation-similarity method and attribute AHM method[J].Shanxi Med J(山西医药杂志),2004,33(6):492-494.
[14]Xing R,Song JW,Xu J,et al.Evaluation on cefperazone-sulbactam drug administration based on weighted TOPSIS method[J].Chin Hosp Pharm J(中国医院药学杂志),2014,34(15):1273-1278.
[15]Xing R,Zhu YL,Song JW,et al.Evaluation on meropenem using based on weighted TOPSIS method[J].Chin J New Drugs Clin Rem(中国新药与临床杂志),2013,32(5):389-393.
[16]Wang GF,Li XQ,Liu RF,et al.Establishment and Application of DUE Criteria for Tigecycline in a Hospital[J].J China Pharm(中国药房),2017,28(14):1892-1895.
[17]He Q,Zhu Y,Jiang FF,et al.Clinical curative effect of tigecycline on treatment of pandrug-resistant Acinetobacter baumannii infection in patients with ventilator-associated pneumonia[J].Chin J Nosocomiol(中华医院感染学杂)志,2016,26(6):1229-1231.
[18]Chen HW,Lou YH,Li XY,et al.Clinical study of tigecycline combined with cefoperazone/sulbactam for treatment of intracranial infection with drug-resistant Acinetobacter baumannii[J].Chin J of Infect Control(中国感染控制杂志),2016,15(6):384-392.
[19]Ren W,Li XH,Chu ML,et al.Drug resistance and risk factors analysis of acinetobacter baumannii in intracranial infection isolated in patients with craniotomy[J].Mil Med J S Chin(华南国防医学杂志),2016,30(3):156-159.
[2]Pedersen CA,Schneider PJ,Scheckelhoff DJ.ASHP National Survey of Pharmacy Practice in Hospital Settings:Prescribing and Transcribing-2004[J].Am J Health Syst Pharm,2005,62(4):378-390.
[3]2013 national antibacterial drug clinical application special rectification activities program(2013年全国抗菌药物临床应用专项整治活动方案)[EB/OL].(2013-05-06)[2018-06-04].http://www.moh.gov.cn/mohyzs/s3585/201305/6042979f05cf49609e96410d7314ecae.shtmL.
[4]Antibacterial drug clinical application management method(抗菌药物临床应用管理办法)[EB/OL].(2012-04-24)[2018-06-04].http://www.moh.gov.cn/mohyzs/s3584/201205/54645.shtmL
[5]Guiding Principles for Clinical Application of Antibacterials(2015 Edition)(抗菌药物临床应用指导原则(2015年版)[EB/OL].(2015-07-24)[2018-06-04].http://www.nhfpc.gov.cn/yzygj/s3593/201508/c18e1014de6c45ed9f6f9d592b43db42.shtmL.
[6]Qu XY,Zhang SX,Yan HY,et al.Meta-analysis of safety induced by tigecycline in the therapy of infectious diseases[J].Chin J Pharmacoepidemiol(药物流行病学杂志),2015,24(3):142-147,151.
[7]Song Z,Xu YG,Xia XY,et al.Two cases of tigecycline in the treatment of intracranial infection caused by pan-resistant Acinetobacter baumannii[J].Chin J Neurotrauma Surg(Electronic Edition)(中华神经创伤外科电子杂志),2015,1(4):57-58.
[8]Dong W,Xie XQ,Kang Y.The interpretation of guideline of appropriate use of tigecycline[J].Chin J Evid-based Med(中国循证医学杂志),2016,16(1):30-32.
[9]Ramirez J,Dartois N,Gandjini H,et al.Randomized phase 2trial to evaluate the clinical efficacy of two high dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia[J].Antimicrob Agents Chemother,2013,57(4):1756-1762.
[10]Kadoyama K,Sakaeda T,Tamon A,et al.Adverse event profile of tigecycline:data mining of the public version of the U.S.Food and Drug Administration adverse event reporting system[J].Biol Pharm Bull,2012,35(6):967-970.
[11]Liu JB,Qu CY,Wang RH.Comprehensive evaluation and application of Tosis based on attribute AHM[J].Modern Preventive Msdicine(现代预防医学),2006,33(10):1862-1863.
[12]Wan F,Song JP.Application of Weighted TOPSIS Method in Comprehensive Evaluation of Hospital Medical Quality[J].Chin J Hosp Statistics(中国医院统计),2010,17(4):297-298.
[13]Li JM,Liu QO,Qu CY.Method for determining the weights of two indicators in comprehensive evaluation-similarity method and attribute AHM method[J].Shanxi Med J(山西医药杂志),2004,33(6):492-494.
[14]Xing R,Song JW,Xu J,et al.Evaluation on cefperazone-sulbactam drug administration based on weighted TOPSIS method[J].Chin Hosp Pharm J(中国医院药学杂志),2014,34(15):1273-1278.
[15]Xing R,Zhu YL,Song JW,et al.Evaluation on meropenem using based on weighted TOPSIS method[J].Chin J New Drugs Clin Rem(中国新药与临床杂志),2013,32(5):389-393.
[16]Wang GF,Li XQ,Liu RF,et al.Establishment and Application of DUE Criteria for Tigecycline in a Hospital[J].J China Pharm(中国药房),2017,28(14):1892-1895.
[17]He Q,Zhu Y,Jiang FF,et al.Clinical curative effect of tigecycline on treatment of pandrug-resistant Acinetobacter baumannii infection in patients with ventilator-associated pneumonia[J].Chin J Nosocomiol(中华医院感染学杂)志,2016,26(6):1229-1231.
[18]Chen HW,Lou YH,Li XY,et al.Clinical study of tigecycline combined with cefoperazone/sulbactam for treatment of intracranial infection with drug-resistant Acinetobacter baumannii[J].Chin J of Infect Control(中国感染控制杂志),2016,15(6):384-392.
[19]Ren W,Li XH,Chu ML,et al.Drug resistance and risk factors analysis of acinetobacter baumannii in intracranial infection isolated in patients with craniotomy[J].Mil Med J S Chin(华南国防医学杂志),2016,30(3):156-159.